Skip to search formSkip to main content

CpG 7909

Known as: CpG-7909, CpG7909 
A synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. CpG 7909 selectively targets… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
T cells with specificity for antigens derived from Wilms Tumor gene (WT1), Proteinase3 (Pr3), and mucin1 (MUC1) have been… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2010
2010
Potent helper action is necessary for peptide-based vaccines to efficiently induce antitumor immune responses against advanced… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Peptide-based vaccines have led to the induction of antigen-specific CD8(+) T-cell responses in patients with NY-ESO-1 positive… Expand
Is this relevant?
2008
2008
BACKGROUND Human immunodeficiency virus (HIV)-infected persons are hyporesponsive to hepatitis B virus (HBV) vaccination. CPG… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2007
Review
2007
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate… Expand
Is this relevant?
2007
2007
CpG oligodeoxynucleotides are potent immunostimulants. In this study, CPG 7909 was formulated with the recombinant Plasmodium… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
CPG 7909, a 24-mer B-Class CpG oligodeoxynucleotide (ODN), was tested for safety, tolerability and its ability to augment the… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Subcutaneous injection of normal human volunteers with a B-class CpG oligodeoxynucleotide (ODN) TLR9 agonist, CPG 7909, induced a… Expand
Is this relevant?
Review
2004
Review
2004
Mycosis Fungoides and Sézary Syndrome are the most common types of cutaneous T-cell lymphomas. There is no current standard of… Expand
Is this relevant?
2003
2003
Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of… Expand
Is this relevant?